HudsonAlpha Institute

ORIEN Cancer Initiative, HudsonAlpha collaborate on personalized cancer therapies

Wednesday, September 14, 2016

The Oncology Research Information Exchange Network (ORIEN), an alliance of cancer centers throughout the U.S., and HudsonAlpha Institute of Biotechnology, a nonprofit research institute, have announced a new collaboration to advance cancer research and care. Under the agreement, HudsonAlpha will provide genomic sequencing services for the ORIEN Avatar Research Program. The program allows the nation’s leading cancer centers to optimize and enable novel treatments and clinical trials, which could have the potential to impact millions of patients worldwide.

[Read More]

Grants to help target genomic variants

Wednesday, September 23, 2015

Six new grants from the National Institutes of Health will support researchers to develop new computational approaches for searching among millions of genomic variants to find those that make a difference in disease susceptibility or in other traits. The awards are for three years each, and total about $13 million, pending the availability of funds. They are administered by the National Human Genome Research Institute (NHGRI) and the National Cancer Institute, both parts of NIH.

[Read More]

Undiagnosed Diseases Network launches online application portal

Thursday, September 17, 2015

The Undiagnosed Diseases Network (UDN), a clinical research initiative of the National Institutes of Health, has opened an online patient application portal called the UDN Gateway. Introduction of this application system sets the stage for the network to advance its core mission: to diagnose patients who suffer from conditions that even skilled physicians have been unable to diagnose despite extensive clinical investigation. These diseases are difficult for doctors to diagnose because they are rarely seen, have not previously been described or are unrecognized forms of more common diseases.

[Read More]

Biogen Idec to discontinue development of ALS drug

Friday, January 4, 2013

Weston, Mass.-based Biogen Idec has decided to discontinue development of dexpramipexole in amyotrophic lateral sclerosis (ALS), after top-line results of EMPOWER, its phase III trial, did not meet its primary endpoint, a joint rank analysis of function and survival, and no efficacy was seen in the individual components of function or survival.

[Read More]